Literature DB >> 21395642

Drug discovery: lessons from evolution.

John Warren1.   

Abstract

A common view within the pharmaceutical industry is that there is a problem with drug discovery and we should do something about it. There is much sympathy for this from academics, regulators and politicians. In this article I propose that lessons learnt from evolution help identify those factors that favour successful drug discovery. This personal view is influenced by a decade spent reviewing drug development programmes submitted for European regulatory approval. During the prolonged gestation of a new medicine few candidate molecules survive. This process of elimination of many variants and the survival of so few has much in common with evolution, an analogy that encourages discussion of the forces that favour, and those that hinder, successful drug discovery. Imagining a world without vaccines, anaesthetics, contraception and anti-infectives reveals how medicines revolutionized humanity. How to manipulate conditions that favour such discoveries is worth consideration.
© 2011 The Author. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Mesh:

Substances:

Year:  2011        PMID: 21395642      PMCID: PMC3080636          DOI: 10.1111/j.1365-2125.2010.03854.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

Review 1.  Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias.

Authors:  D J Weatherall
Journal:  Nat Rev Genet       Date:  2001-04       Impact factor: 53.242

2.  Clinical pharmacology: the scientific basis of therapeutics.

Authors:  M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1999-07       Impact factor: 6.875

3.  Hope in translation.

Authors: 
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

4.  Financing medical education. A universal "Berry Plan" for medical students.

Authors:  R G Petersdorf
Journal:  N Engl J Med       Date:  1993-03-04       Impact factor: 91.245

Review 5.  The quest for a cure.

Authors:  G B Elion
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

6.  Therapeutic-class wars--drug promotion in a competitive marketplace.

Authors:  D A Kessler; J L Rose; R J Temple; R Schapiro; J P Griffin
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

7.  The story of "the Berry Plan".

Authors:  F B Berry
Journal:  Bull N Y Acad Med       Date:  1976 Mar-Apr

8.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

Review 9.  Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.

Authors:  Razelle Kurzrock; Hagop M Kantarjian; Brian J Druker; Moshe Talpaz
Journal:  Ann Intern Med       Date:  2003-05-20       Impact factor: 25.391

10.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

View more
  1 in total

Review 1.  Population Modelling in Affective Disorders.

Authors:  Erdem Pulcu
Journal:  Curr Behav Neurosci Rep       Date:  2021-04-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.